Poolbeg Pharma PLC

Equities

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:14 2024-05-31 am EDT			5-day change	1st Jan Change
13.7 ^GBX	+4.58%		+4.58%	+51.38%

May. 01	Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	MT
May. 01	Poolbeg Pharma celebrates full patent approval for Immunomodulator II	AN

Poolbeg Pharma appoints former Amryt executives to team

November 09, 2023 at 11:58 am EST

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma.

David Allmond will join Poolbeg as chief business officer from December 1. Allmond previously held the same role at Amryt. John McEvoy will become senior vice president, chief legal officer, from January 1. McEvoy was global general counsel at Amryt from 2017. Finally, Laura Maher will join as vice president of clinical operations from January 8. Maher joined Amryt in 2018, and as associate director of clinical operations, led the clinical research programmes for multiple products.

Current stock price: 8.03 pence, up 19% on Thursday in London

12-month change: up 8.5%

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Poolbeg Pharma PLC

Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	May. 01	MT
Poolbeg Pharma celebrates full patent approval for Immunomodulator II	May. 01	AN
Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application	May. 01	CI
Poolbeg Pharma Signs Option Deal to Buy Orphan Drug Candidate from Silk Road Therapeutics	Apr. 30	MT
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	Apr. 30	AN
Earnings Flash (POLB.L) POOLBEG PHARMA Posts FY23 Loss GBX-0.79	Apr. 30	MT
EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake	Mar. 20	AN
Poolbeg Pharma plc Announces POLB 001 US Patent Update	Mar. 20	CI
Diversified Energy offers dividend alternative	Feb. 15	AN
Poolbeg Pharma's Nonexecutive Chair Transitions to Executive Role	Feb. 15	MT
Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman	Feb. 15	CI
Katoro Gold launches fundraising, eyes board shake-up	Feb. 12	AN
Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome	Feb. 12	CI
Poolbeg Pharma Therapy Shows Efficacy in Lowering Cancer Immunotherapy-induced Cytokine Release Syndrome	Jan. 17	MT
Poolbeg Pharma hails POLB 001'S potential to treat CRS	Jan. 17	AN
Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome	Jan. 17	CI
K3 Business says cash balances ahead of forecast	Dec. 20	AN
Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully	Dec. 20	CI
Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001	Dec. 11	CI
Poolbeg Pharma plc Announces Directorate Changes	Nov. 30	CI
Poolbeg hails approval; EDX links with Thermo Fisher	Nov. 21	AN
Poolbeg Pharma appoints former Amryt executives to team	Nov. 09	AN
Poolbeg Pharma Names Business, Legal Chiefs	Nov. 09	MT
Poolbeg Pharma plc Announces Executive Appointments	Nov. 09	CI
Poolbeg Pharma plc Announces Scientific Advisory Board Endorses Influenza Drug Targets Identified in Ai Drug Discovery Programme	23-10-26	CI

Chart Poolbeg Pharma PLC

Duration

Period

More charts

Company Profile

Poolbeg Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The Company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-06-02 - BIO International Convention

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.137 GBP

Average target price

0.21 GBP

Spread / Average Target

+53.28%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
POOLBEG PHARMA PLC	+51.38%	87.16M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs